贝伐珠单抗联合奥沙利铂与卡培他滨治疗晚期结直肠癌对患者生活质量及不良反应的影响  

Effects of Bevacizumab Combined with Oxaliplatin and Capecitabine on Quality of Life and Adverse Effects in Patients with Advanced Colorectal Cancer

作　　者：尹敏[1] 陈晶晶[1] 于德洪[1] YIN Min;CHEN Jingjing;YU Dehong(Department of Oncology Radiotherapy,Pizhou People's Hospital,Pizhou,Jiangsu Province,221300 China)

机构地区：[1]邳州市人民医院肿瘤放疗科,江苏邳州221300

出　　处：《系统医学》2023年第4期168-171,共4页Systems Medicine

基　　金：徐州市卫生健康委科技项目(XWKYSL20210233)。

摘　　要：目的分析将贝伐珠单抗+奥沙利铂+卡培他滨用于晚期结直肠癌治疗中的临床价值。方法选择2020年5月—2022年12月在邳州市人民医院接受治疗的72例结直肠癌患者为研究对象,以随机数表法分为对照组(36例,奥沙利铂+卡培他滨治疗)、观察组(36例,基于对照组增加贝伐珠单抗治疗)。对比两组疗效、肿瘤标志物水平、生存质量及不良反应情况。结果观察组客观缓解率为36.11%,高于对照组的13.89%,差异有统计学意义(χ^(2)=4.741,P<0.05)。治疗前,两组CEA、CA199、CA72-4水平比较,差异无统计学意义(P>0.05);治疗后,观察组CEA、CA199、CA72-4水平低于对照组,差异有统计学意义(P<0.05)。治疗前,两组Karnofsk评分比较,差异无统计学意义(P>0.05);治疗后,观察组Karnofsk评分为(86.79±4.25)分,高于对照组的(80.56±3.47)分,差异有统计学意义(t=6.813,P<0.05)。两组不良反应发生率分别为41.67%、36.11%,差异无统计学意义(χ^(2)=0.234,P>0.05)。结论将贝伐珠单抗+奥沙利铂+卡培他滨用于晚期结直肠癌治疗的效果显著,可提高患者生存质量,且安全性较高。Objective To analyze the clinical value of using bevacizumab+oxaliplatin+capecitabine in the treatment of advanced colorectal cancer.Methods Seventy-two patients with colorectal cancer who received treatment in Pizhou People's Hospital from May 2020 to December 2022 were selected as the study subjects.They were divided into control group(36 cases receiving oxaliplatin+capecitabine treatment)and observation group(36 cases receiving beizumab treatment based on the control group)by random number table method.The efficacy,tumor marker levels,quality of life and adverse reactions were compared between the two groups.Results The objective response rate in the observation group was 36.11%,higher than that of control group 13.89%,the difference was statistically significant(χ^(2)=4.741,P<0.05).Before treatment,there was no statistically significant difference in CEA,CA199 and CA72-4 levels between the two groups(P>0.05).After treatment,CEA,CA199 and CA72-4 levels in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in Karnofsk scores between the two groups(P>0.05).After treatment,the Karnofsk score of the observation group was(86.79±4.25)points,which was higher than that of the control group(80.56±3.47)points,and the difference was statistically significant(t=6.813,P<0.05).Two groups of adverse reaction rate were 41.67%,36.11%,the difference was not statistically significant(χ^(2)=0.234,P>0.05).Conclusion Bevacizumab+oxaliplatin+capecitabine has a significant effect in the treatment of advanced colorectal cancer,which can improve the quality of life of patients with high safety.

关 键 词：贝伐珠单抗 奥沙利铂 卡培他滨 晚期结直肠癌 生活质量 不良反应 

分 类 号：R735[医药卫生—肿瘤]